Drug Profile
EGIS 3966
Latest Information Update: 31 Mar 1995
Price :
$50
*
At a glance
- Originator Egis Pharmaceuticals
- Developer Japan Tobacco
- Class Antiarrhythmics
- Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 31 Mar 1995 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)
- 31 Mar 1995 Discontinued-Preclinical for Arrhythmias in Philippines (Unknown route)
- 31 Mar 1995 Discontinued-Preclinical for Arrhythmias in South Korea (Unknown route)